Cargando…

Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens

Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashu, Rasheduzzaman, Ninkov, Marina, Wardell, Christine M., Benoit, Jenna M., Wang, Nicole I., Meilleur, Courtney E., D’Agostino, Michael R., Zhang, Ali, Feng, Emily, Saeedian, Nasrin, Bell, Gillian I., Vahedi, Fatemeh, Hess, David A., Barr, Stephen D., Troyer, Ryan M., Kang, Chil-Yong, Ashkar, Ali A., Miller, Matthew S., Haeryfar, S. M. Mansour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337970/
https://www.ncbi.nlm.nih.gov/pubmed/37384813
http://dx.doi.org/10.1371/journal.ppat.1011485
_version_ 1785071532095045632
author Rashu, Rasheduzzaman
Ninkov, Marina
Wardell, Christine M.
Benoit, Jenna M.
Wang, Nicole I.
Meilleur, Courtney E.
D’Agostino, Michael R.
Zhang, Ali
Feng, Emily
Saeedian, Nasrin
Bell, Gillian I.
Vahedi, Fatemeh
Hess, David A.
Barr, Stephen D.
Troyer, Ryan M.
Kang, Chil-Yong
Ashkar, Ali A.
Miller, Matthew S.
Haeryfar, S. M. Mansour
author_facet Rashu, Rasheduzzaman
Ninkov, Marina
Wardell, Christine M.
Benoit, Jenna M.
Wang, Nicole I.
Meilleur, Courtney E.
D’Agostino, Michael R.
Zhang, Ali
Feng, Emily
Saeedian, Nasrin
Bell, Gillian I.
Vahedi, Fatemeh
Hess, David A.
Barr, Stephen D.
Troyer, Ryan M.
Kang, Chil-Yong
Ashkar, Ali A.
Miller, Matthew S.
Haeryfar, S. M. Mansour
author_sort Rashu, Rasheduzzaman
collection PubMed
description Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unclear. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster virus-specific CD8(+) T cell responses, and potentiate heterosubtypic anti-influenza protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency and Toll-like receptor 3 and type I interferon receptor signaling. The observed phenomenon was reproducible in female and male mice, and in both young and old animals. It could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses.
format Online
Article
Text
id pubmed-10337970
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-103379702023-07-13 Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens Rashu, Rasheduzzaman Ninkov, Marina Wardell, Christine M. Benoit, Jenna M. Wang, Nicole I. Meilleur, Courtney E. D’Agostino, Michael R. Zhang, Ali Feng, Emily Saeedian, Nasrin Bell, Gillian I. Vahedi, Fatemeh Hess, David A. Barr, Stephen D. Troyer, Ryan M. Kang, Chil-Yong Ashkar, Ali A. Miller, Matthew S. Haeryfar, S. M. Mansour PLoS Pathog Research Article Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unclear. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster virus-specific CD8(+) T cell responses, and potentiate heterosubtypic anti-influenza protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency and Toll-like receptor 3 and type I interferon receptor signaling. The observed phenomenon was reproducible in female and male mice, and in both young and old animals. It could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses. Public Library of Science 2023-06-29 /pmc/articles/PMC10337970/ /pubmed/37384813 http://dx.doi.org/10.1371/journal.ppat.1011485 Text en © 2023 Rashu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rashu, Rasheduzzaman
Ninkov, Marina
Wardell, Christine M.
Benoit, Jenna M.
Wang, Nicole I.
Meilleur, Courtney E.
D’Agostino, Michael R.
Zhang, Ali
Feng, Emily
Saeedian, Nasrin
Bell, Gillian I.
Vahedi, Fatemeh
Hess, David A.
Barr, Stephen D.
Troyer, Ryan M.
Kang, Chil-Yong
Ashkar, Ali A.
Miller, Matthew S.
Haeryfar, S. M. Mansour
Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title_full Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title_fullStr Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title_full_unstemmed Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title_short Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
title_sort targeting the mr1-mait cell axis improves vaccine efficacy and affords protection against viral pathogens
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337970/
https://www.ncbi.nlm.nih.gov/pubmed/37384813
http://dx.doi.org/10.1371/journal.ppat.1011485
work_keys_str_mv AT rashurasheduzzaman targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT ninkovmarina targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT wardellchristinem targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT benoitjennam targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT wangnicolei targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT meilleurcourtneye targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT dagostinomichaelr targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT zhangali targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT fengemily targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT saeediannasrin targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT bellgilliani targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT vahedifatemeh targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT hessdavida targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT barrstephend targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT troyerryanm targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT kangchilyong targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT ashkaralia targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT millermatthews targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens
AT haeryfarsmmansour targetingthemr1maitcellaxisimprovesvaccineefficacyandaffordsprotectionagainstviralpathogens